ArticleTherapeutic advances in gastroenterology2021

Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab.

Sarah Fischer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.